Press Releases

KemPharm® is a clinical stage, specialty pharmaceutical company engaged in the development and discovery of proprietary prodrugs that are designed to be improved versions of widely prescribed and FDA approved products.

Press Releases

News Releases

Date Title and Summary
Toggle Summary KemPharm’s KP415 and Serdexmethylphenidate (SDX) Prodrug to be Featured in Multiple Sessions at the AACAP 2020 Virtual Meeting
CELEBRATION, Fla. , Oct. 22, 2020 (GLOBE NEWSWIRE) -- KemPharm, Inc. (OTCQB: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced that research involving KP415 and serdexmethylphenidate (SDX) will be featured in two oral
Toggle Summary KemPharm and Corium Expand Relationship with New Consultation Services Agreement
New agreement provides additional revenue potentially through Q1 2022 CELEBRATION, Fla. , Oct. 05, 2020 (GLOBE NEWSWIRE) -- KemPharm, Inc. (OTCQB: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced that it has expanded its
Toggle Summary KemPharm Files Preliminary Proxy for Special Meeting of Stockholders
CELEBRATION, Fla. , Sept. 25, 2020 (GLOBE NEWSWIRE) -- KemPharm, Inc. ( KemPharm , or the Company) (OTCQB: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today filed a preliminary proxy statement on Schedule 14A (the Preliminary Proxy
Toggle Summary KemPharm’s Commercial Partner for APADAZ®, KVK-Tech, Enters into Collaboration Agreement with Sure Med Compliance Focused on Improving Prescribing Education and Compliance for Pain Therapies
Pilot program initially launching in Alabama aligns APADAZ with Sure Med’s Care Continuity Program ® to collect data and create a more informed opioid prescribing environment CELEBRATION, Fla. , Sept. 10, 2020 (GLOBE NEWSWIRE) -- KemPharm, Inc. (OTCQB: KMPH), a specialty pharmaceutical company
Toggle Summary KemPharm to Present at Upcoming September Investor Conferences
Presentations to Highlight Corporate, Regulatory and Pipeline Advancements CELEBRATION, Fla. , Sept. 02, 2020 (GLOBE NEWSWIRE) -- KemPharm, Inc. (OTCQB: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced that its president and
Toggle Summary KemPharm Participates in KP415 Mid-Cycle Communication Meeting with FDA
CELEBRATION, Fla. , Aug. 14, 2020 (GLOBE NEWSWIRE) -- KemPharm, Inc. (OTCQB: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced that the Company participated in a mid-cycle communication meeting on August 13, 2020 , with the
Toggle Summary KemPharm Reports Second Quarter 2020 Financial Results
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 4:30 p.m. ET Corporate and Regulatory Highlights: Received Day-74 Letter for KP415 NDA; FDA has set PDUFA date of March 2, 2021 Announced that Corium, Inc. , a portfolio company of GPC, will lead all
Toggle Summary KemPharm to Report Second Quarter 2020 Financial Results
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Wednesday, August 12, 2020, 4:30 p.m. ET CELEBRATION, Fla. , Aug. 04, 2020 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary
Toggle Summary KemPharm Announces Issuance of Two Additional U.S. Patents Governing KP415 and KP484
New Patent Issuance Extends SDX Patent Life for an Additional Five Years until 2037 CELEBRATION, Fla. , July 28, 2020 (GLOBE NEWSWIRE) -- KemPharm, Inc. (OTCQB: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced that the
Toggle Summary KemPharm Issues Letter to Shareholders
CELEBRATION, Fla. , June 18, 2020 (GLOBE NEWSWIRE) -- KemPharm, Inc. (OTCQB: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced that Travis C. Mickle , Ph.D., President and CEO of KemPharm , has issued a Letter to Shareholders